Literature DB >> 8800449

Limitation of infarct size with preconditioning and calcium antagonist (diltiazem): difference in 99mTc-PYP uptake in the myocardium.

K Okuda1, R Nohara, M Ogino, N Tamaki, J Konishi, M Fujita, S Sasayama.   

Abstract

UNLABELLED: Ischemic cell injury and the uptake mechanism of 99mTc-PYP (Pyrophosphate) were studied with preconditioning and calcium antagonist.
METHOD: The coronary artery of an adult mongrel dog was clamped for 1 hour, followed by reperfusion and 99mTc-PYP injection. A control group (group C, n = 8), a group in which continuous drip infusion of diltiazem (10 mg/kg) (group D, n = 7), and a group preconditioned by six 5-minute clampings and perfusions before occlusion (group P, n = 6) were compared.
RESULTS: Wall motion was fully recovered in group D but not in group P after 2 hours of reperfusion. The 99mTc-PYP uptake ratio showed a significant (p < 0.05) reduction in group D (11.5 : 3.6 compared with group C), but not in group P (11.5 : 9.1, p = 0.25). The infarct area was 1.2 +/- 0.6% of the left ventricle in group D, 1.3 +/- 0.4 in group P, and 6.4 +/- 1.0 in group C (p < 0.01 in groups D and P vs. group C).
CONCLUSIONS: These findings suggest that preconditioning does not alleviate stunning, but it improves cell injury in spite of high uptake of 99mTc-PYP. Diltiazem protects from both stunning and cell injury, suggesting a different mechanism of myocardial protection from that of preconditioning.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8800449     DOI: 10.1007/bf03165393

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  32 in total

1.  Preconditioning does not attenuate myocardial stunning.

Authors:  M Ovize; K Przyklenk; S L Hale; R A Kloner
Journal:  Circulation       Date:  1992-06       Impact factor: 29.690

Review 2.  Cardioprotective effects of captopril in myocardial ischaemia, ischaemia/reperfusion and infarction.

Authors:  P M Mehta; K Przyklenk; R A Kloner
Journal:  Eur Heart J       Date:  1990-04       Impact factor: 29.983

3.  Regional myocardial functional and electrophysiological alterations after brief coronary artery occlusion in conscious dogs.

Authors:  G R Heyndrickx; R W Millard; R J McRitchie; P R Maroko; S F Vatner
Journal:  J Clin Invest       Date:  1975-10       Impact factor: 14.808

4.  Repetitive episodes of brief ischaemia (12 min) do not produce a cumulative depletion of high energy phosphate compounds.

Authors:  J L Swain; R L Sabina; J J Hines; J C Greenfield; E W Holmes
Journal:  Cardiovasc Res       Date:  1984-05       Impact factor: 10.787

5.  Detection of unstable angina by 99m technetium pyrophosphate myocardial scintigraphy.

Authors:  A M Abdulla; M I Canedo; B C Cortez; K D McGinnis; S K Wilhelm
Journal:  Chest       Date:  1976-02       Impact factor: 9.410

6.  Staged reperfusion attenuates myocardial stunning in dogs. Role of transient acidosis during early reperfusion.

Authors:  M Hori; M Kitakaze; H Sato; S Takashima; K Iwakura; M Inoue; A Kitabatake; T Kamada
Journal:  Circulation       Date:  1991-11       Impact factor: 29.690

7.  Preconditioning improves energy metabolism during reperfusion but does not attenuate myocardial stunning in porcine hearts.

Authors:  M Miyamae; H Fujiwara; M Kida; R Yokota; M Tanaka; M Katsuragawa; K Hasegawa; M Ohura; K Koga; Y Yabuuchi
Journal:  Circulation       Date:  1993-07       Impact factor: 29.690

8.  Effect of intracoronary diltiazem on infarct size and regional myocardial function in the ischemic reperfused canine heart.

Authors:  L Higginson; A Tang; G Knoll; J Calvin
Journal:  J Am Coll Cardiol       Date:  1991-09       Impact factor: 24.094

9.  Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs.

Authors:  G J Gross; J A Auchampach
Journal:  Circ Res       Date:  1992-02       Impact factor: 17.367

10.  Myocardial protection with preconditioning.

Authors:  G C Li; J A Vasquez; K P Gallagher; B R Lucchesi
Journal:  Circulation       Date:  1990-08       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.